What's Happening?
CARSgen Therapeutics has achieved a significant milestone by obtaining approval from China's National Medical Products Administration (NMPA) for its CAR-T therapy, satricabtagene autoleucel (satri-cel). This marks the first time a CAR-T therapy has been
approved globally for the treatment of a solid tumour. The therapy targets claudin 18.2-positive, HER2-negative advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma in patients who have not responded to at least two prior treatments. The approval is based on a phase 2 trial published in The Lancet, which demonstrated a notable improvement in progression-free survival compared to standard care. CARSgen is also conducting further trials to explore the therapy's potential in other cancers and earlier stages of gastric and GEJ cancers.
Why It's Important?
This approval is a breakthrough in the field of oncology, particularly for the treatment of solid tumours, which have historically been challenging for CAR-T therapies. The success of satri-cel could pave the way for new treatment options for patients with advanced gastric cancer, a disease with high incidence and mortality rates, especially in Asia. The therapy's approval highlights the potential of targeting claudin 18.2, a biomarker that could be significant in treating various cancers. This development may influence future research and investment in CAR-T therapies for solid tumours, potentially leading to more effective treatments for other types of cancer.
What's Next?
CARSgen is expanding its clinical trials to include earlier-line treatments and is exploring the therapy's use in other cancers such as pancreatic and biliary tract cancers. Internationally, the company is conducting phase 1/2 trials and has received FDA orphan drug and regenerative medicine advanced therapy designations. Additionally, CARSgen is collaborating with Moderna to investigate the combination of satri-cel with an investigational mRNA cancer vaccine. These efforts could lead to broader applications of the therapy and further advancements in cancer treatment.
